W. R. Grace & Company and FORMAC Pharmaceuticals NV Announce Successful Clinical Trial Demonstrating the Novel Use of Silica for Drug Delivery
COLUMBIA, Md.--(BUSINESS WIRE)--W. R. Grace & Co. (NYSE: GRA), in partnership with Formac Pharmaceuticals NV, a research and development pharmaceutical company, announced today positive data from initial human studies enabled by the companies’ unique mesoporous silica-based drug delivery technology. This novel technology opens up a viable new avenue for the development of poorly soluble compounds.